Back to News
Market Impact: 0.35
Aclaris Therapeutics, Inc. Enters Underwriting Agreement for Offering of 7,785,714 Shares of Common Stock and 6,500,000 Pre-Funded Warrants
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
On October 27, 2026, Aclaris Therapeutics entered an underwriting agreement to issue and sell 7,785,714 common shares and pre-funded warrants to purchase 6,500,000 additional shares. The article gives an offering price of $3.5, but the text ends before specifying further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
ACRS-0.30
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target